Skip to main content

Table 2 Two-tailed T-test before and after Placebo infusion on LV function after 2 months of AR in a rat model (n = 5)

From: Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats

 

Before infusion

After infusion

p-value

Heart Rate (beats/min)

249 ± 18

220 ± 41

0.437

Left Atrium (mm)

6.2 ± 0.8

5.8 ± 1.1

0.541

LVEDD (mm)

10.6 ± 0.8

12.24 ± 1.07

0.092

LVESD (mm)

7.5 ± 0.6

6.9 ± 0.84

0.341

FS (%)

28.8 ± 1.4

29.6 ± 5.2

0.706

EF (%)

60.8 ± 1.8

61.0 ± 8.4

0.968

Stroke Volume (ml)

0.24 ± 0.04

0.24 + 0.08

0.890

Cardiac Output (ml/min)

60 ± 8

60 ± 12

0.369

SWTs (mm)

3.0 ± 0.16

2.9 ± 0.47

0.122

SWTd (mm)

1.6 ± 0.17

1.7 ± 0.29

0.281

Systolic time (ms)

136 ± 5

123 ± 17

0.340

Diastolic time (ms)

144 ± 24

173 ± 41

0.054

PEP (ms)

25.8 ± 4.6

21.2 ± 6.2

0.125

LVET (ms)

110 ± 8

102 ± 14

0.490

PEP/LVET

0.24 ± 0.05

0.20 ± 0.05

0.182

Systolic time/RR

0.49 ± 0.05

0.42 ± 0.05

0.047

  1. Values are mean ± SD. Left ventricle end-diastolic diameter; LVEDV: Left ventricle end-diastolic volume; LVESD: Left ventricle end-systolic diameter; LVESD: Left ventricle end-systolic volume; FS: Fractional shortening; EF: Ejection fraction; SV: stroke volume; SWTs: septal wall thickness at end-systole; SWTd: septal wall thickness at end-diastole PEP: aortic pre-ejection period; LVET: Left ventricular ejection time; RR: inter-beat interval